EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Dual energy for pulmonary vein isolation using focal ablation technology integrated with a three-dimensional mapping system: SmartfIRE 12-month results

Tom De Potter iD, Daniel Scherr iD, Helmut Pürerfellner iD, Gediminas Račkauskas iD, Jim Hansen iD, Johan Vijgen iD, Thomas Phlips iD, Sebastien Knecht iD, Gabor Szeplaki iD, Hugo Van Herendael iD, Mads Brix Kronborg iD, Benjamin Berte iD und 5 weitere

Europace · 01.09.2025 · 27 (9)

DOI: 10.1093/europace/euaf174 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Europace, online erschienen am 12.08.2025. Verfasst von Tom De Potter und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, AZORG, Moorselbaan 164, 9300 Aalst, Belgium. Hauptthemen laut MEDLINE: Pulmonary Veins, Atrial Fibrillation, Catheter Ablation, Imaging, Three-Dimensional. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biosense Webster, Inc., Johnson & Johnson MedTech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The multicentre, single-arm SmartfIRE study assessed the safety and effectiveness of the novel dual-energy THERMOCOOL SMARTTOUCH SF (DE STSF) contact-force sensing catheter with multimodality generator to deliver radiofrequency (RF) and unipolar biphasic pulsed field (PF) ablation. Three-month follow-up showed a 100% acute success rate with an acceptable safety profile. Results at 12 months postablation are summarized here. Methods and results Patients with symptomatic paroxysmal atrial fibrillation underwent pulmonary vein isolation with the recommendation of PF ablation at posterior/inferior and RF ablation at the anterior/ridge/carina segments. The 12-month effectiveness endpoint was freedom from documented symptomatic and asymptomatic atrial arrhythmia on or off antiarrhythmic therapy (assessed by electrocardiogram, remote arrhythmia monitoring, and 24-h Holter), including acute procedural failures. Safety was assessed as the incidence of serious adverse events (SAEs) related to device and/or procedure. Quality of life was evaluated via Atrial Fibrillation Effect on Quality-of-Life (AFEQT) scores, and healthcare utilization was assessed as hospitalization for cardiovascular events and antiarrhythmic drug (AAD) use. Of 149 patients enrolled, 140 had the study catheter inserted (safety population analysis set), and 136 met the eligibility criteria and had ablation energy delivered (per-protocol analysis set). Freedom from symptomatic and asymptomatic atrial arrhythmia at 12 months was 71.5% (84.2% when using standard-of-care monitoring only). The clinical success rate (freedom from symptomatic arrhythmia) was 86.4%, and single procedural success was 81.0% (n = 136). The rate of device- and/or procedure-related SAEs was 3.6% (5/140 patients; two cardiac tamponades, two pulmonary vein stenosis, one anaphylactic shock). At 12 months, the overall AFEQT score increased by a median 26.9 points vs. baseline. Cardiovascular hospitalization rate reduced from 20.1 to 11.9% during the 12 months before vs. after ablation, respectively. The use of Class I/III AAD decreased from 60.3% at baseline to 23.9% at 6–12 months postablation. Post hoc analysis showed that patients with high adherence to recommended inter-tag distance and PF/RF index during ablation (n = 47) had a 12-month freedom from atrial arrhythmia recurrence of 86.9%, while the remaining patients (n = 88) had a rate of 64.0%.

Conclusion

The 12-month follow-up of the SmartfIRE study demonstrated the effectiveness, safety, and healthcare benefits of ablation using the DE STSF platform. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT05752487 (https://clinicaltrials.gov/study/NCT05752487)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary VeinsAtrial FibrillationCatheter AblationImaging, Three-DimensionalCardiac CathetersElectrophysiologic Techniques, CardiacHumansMaleFemaleMiddle AgedAgedTreatment OutcomeTime FactorsQuality of LifeAction PotentialsElectrocardiography, AmbulatoryEquipment DesignAnti-Arrhythmia Agents

Stichwörter der Autor:innen

Ablation indexContact force catheterDual energyPulmonary vein isolationPulsed field ablation

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Cardiovascular Center, AZORG, Moorselbaan 164, 9300 Aalst, Belgium.
  • Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Department of Cardiology and Electrophysiology, Ordensklinikum Linz Elisabethinen, Linz, Austria.
  • Vilnius University Hospital, Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
  • Department of Cardiology, Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.
  • Cardiology Department, Jessa Hospitals, Hasselt, Belgium.

ORCID-Profile: Tom De Potter, Daniel Scherr, Helmut Pürerfellner, Gediminas Račkauskas, Jim Hansen, Johan Vijgen, Thomas Phlips, Sebastien Knecht, Gabor Szeplaki, Hugo Van Herendael, Mads Brix Kronborg, Benjamin Berte, Martin Ruwald, Georgios Kollias, Tiffany Tan, Mattias Duytschaever

Förderung

  • Biosense Webster, Inc.
  • Johnson & Johnson MedTech

Zitieren

APA

De Potter, T., Scherr, D., Pürerfellner, H., Račkauskas, G., Hansen, J., Vijgen, J., Phlips, T., Knecht, S., Szeplaki, G., Van Herendael, H., Kronborg, M. B., Berte, B., Ruwald, M., Kollias, G., Lukac, P., Tan, T., & Duytschaever, M. (2025). Dual energy for pulmonary vein isolation using focal ablation technology integrated with a three-dimensional mapping system: SmartfIRE 12-month results. Europace, 27(9). https://doi.org/10.1093/europace/euaf174

Vancouver

De Potter T, Scherr D, Pürerfellner H, Račkauskas G, Hansen J, Vijgen J, et al. Dual energy for pulmonary vein isolation using focal ablation technology integrated with a three-dimensional mapping system: SmartfIRE 12-month results. Europace. 2025;27(9). doi:10.1093/europace/euaf174

BibTeX
@article{DePotter2025,
  author = {De Potter, Tom and Scherr, Daniel and Pürerfellner, Helmut and Račkauskas, Gediminas and Hansen, Jim and Vijgen, Johan and Phlips, Thomas and Knecht, Sebastien and Szeplaki, Gabor and Van Herendael, Hugo and Kronborg, Mads Brix and Berte, Benjamin and Ruwald, Martin and Kollias, Georgios and Lukac, Peter and Tan, Tiffany and Duytschaever, Mattias},
  title = {Dual energy for pulmonary vein isolation using focal ablation technology integrated with a three-dimensional mapping system: SmartfIRE 12-month results},
  journal = {Europace},
  year = {2025},
  volume = {27},
  number = {9},
  doi = {10.1093/europace/euaf174}
}
Kostenlos starten →